


**METHOCARBAMOL- methocarbamol tablet, film coated**  
**RPK Pharmaceuticals, Inc.**

-----  
**Methocarbamol Tablets USP, 500 mg and 750 mg**

(Methocarbamol USP)  
Rx Only

**DESCRIPTION**

Methocarbamol Tablets USP, a carbamate derivative of guaifenesin, is a central nervous system (CNS) depressant with sedative and musculoskeletal relaxant properties. The chemical name of methocarbamol is 3 - (2-methoxyphenoxy) -1, 2- propanediol 1- carbamate and has the empirical formula  $C_{11}H_{15}NO_5$ . Its molecular weight is 241.24.



The structural formula is shown below.

Methocarbamol is a white powder, sparingly soluble in water and chloroform, soluble in alcohol (only with heating) and propylene glycol, and insoluble in benzene and n-hexane.

Methocarbamol Tablets USP, 500 mg is available as a light orange colored, round, film-coated tablets, engraved with 'B134' on one side and scored on the other side, containing 500 mg of methocarbamol, USP for oral administration. The inactive ingredients present are corn starch, low substituted hydroxypropyl cellulose, hydroxypropyl cellulose, sodium starch glycolate, povidone, sodium lauryl sulfate, colloidal silicon dioxide, stearic acid, magnesium stearate, and purified water. Methocarbamol Tablets USP, 500 mg contains Opadry 13H530000 (Orange) (hypromellose, titanium dioxide, propylene glycol, FD&C yellow #6/Sunset Yellow FCF Aluminum Lake, polysorbate 20) as coating material.

Methocarbamol Tablets USP, 750 mg is available as an orange colored, capsule shaped, film coated tablets, engraved with 'B135' on one side and plain on the other side, containing 750 mg of methocarbamol, USP for oral administration. It contains Opadry 13H530001 (Orange) as coating material. The inactive ingredients present are corn starch, low substituted hydroxypropyl cellulose, hydroxypropyl cellulose, sodium starch glycolate, povidone, sodium lauryl sulfate, colloidal silicon dioxide, stearic acid, magnesium stearate, and purified water. Methocarbamol Tablets USP, 750 mg contain Opadry 13H530001 (Orange) (hypromellose, titanium dioxide, propylene glycol, D&C Yellow #10 Aluminum Lake, FD&C yellow #6/Sunset Yellow FCC Aluminum Lake, polysorbate 20) as coating material.

**CLINICAL PHARMACOLOGY**

The mechanism of action of methocarbamol in humans has not been established, but may be due to general central nervous system (CNS) depression. It has no direct action

on the contractile mechanism of striated muscle, the motor end plate or the nerve fiber.

## **Pharmacokinetics**

In healthy volunteers, the plasma clearance of methocarbamol ranges between 0.20 and 0.80 L/h/kg, the mean plasma elimination half-life ranges between 1 and 2 hours, and the plasma protein binding ranges between 46% and 50%.

Methocarbamol is metabolized via dealkylation and hydroxylation. Conjugation of methocarbamol also is likely. Essentially all methocarbamol metabolites are eliminated in the urine. Small amounts of unchanged methocarbamol also are excreted in the urine.

## **Special populations**

### **Elderly**

The mean ( $\pm$  SD) elimination half-life of methocarbamol in elderly healthy volunteers (mean ( $\pm$  SD) age, 69 ( $\pm$  4) years) was slightly prolonged compared to a younger (mean ( $\pm$  SD) age, 53.3 ( $\pm$  8.8) years), healthy population (1.5 ( $\pm$  0.4) hours versus 1.1 ( $\pm$  0.27) hours, respectively). The fraction of bound methocarbamol was slightly decreased in the elderly versus younger volunteers (41 to 43% versus 46 to 50%, respectively).

### **Renally impaired**

The clearance of methocarbamol in 8 renally-impaired patients on maintenance hemodialysis was reduced about 40% compared to 17 normal subjects, although the mean ( $\pm$  SD) elimination half-life in these two groups was similar: 1.2 ( $\pm$  0.6) versus 1.1 ( $\pm$  0.3) hours, respectively.

### **Hepatically impaired**

In 8 patients with cirrhosis secondary to alcohol abuse, the mean total clearance of methocarbamol was reduced approximately 70% compared to that obtained in 8 age- and weight-matched normal subjects. The mean ( $\pm$  SD) elimination half-life in the cirrhotic patients and the normal subjects was 3.38 ( $\pm$  1.62) hours and 1.11 ( $\pm$  0.27) hours, respectively. The percent of methocarbamol bound to plasma proteins was decreased to approximately 40 to 45% compared to 46 to 50% in the normal subjects.

## **INDICATIONS AND USAGE**

Methocarbamol Tablets USP, 500 mg and 750 mg are indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions. The mode of action of methocarbamol has not been clearly identified, but may be related to its sedative properties. Methocarbamol does not directly relax tense skeletal muscles in man.

## **CONTRAINDICATIONS**

Methocarbamol Tablets USP, 500 mg and 750 mg are contraindicated in patients hypersensitive to methocarbamol or to any of the tablet components.

## **WARNINGS**

Since methocarbamol may possess a general CNS depressant effect, patients receiving Methocarbamol Tablets USP, 500 mg or 750 mg should be cautioned about combined effects with alcohol and other CNS depressants.

Safe use of Methocarbamol Tablets USP, 500 mg and 750 mg has not been established with regard to possible adverse effects upon fetal development. There have been reports of fetal and congenital abnormalities following in utero exposure to methocarbamol. Therefore, Methocarbamol Tablets USP, 500 mg and 750 mg should not be used in women who are or may become pregnant and particularly during early pregnancy unless in the judgment of the physician the potential benefits outweigh the possible hazards (see PRECAUTIONS, Pregnancy).

### **Use In Activities Requiring Mental Alertness**

Methocarbamol may impair mental and/or physical abilities required for performance of hazardous tasks, such as operating machinery or driving a motor vehicle. Patients should be cautioned about operating machinery, including automobiles, until they are reasonably certain that methocarbamol therapy does not adversely affect their ability to engage in such activities.

## **PRECAUTIONS**

### **Information for Patients**

Patients should be cautioned that methocarbamol may cause drowsiness or dizziness, which may impair their ability to operate motor vehicles or machinery.

Because methocarbamol may possess a general CNS-depressant effect, patients should be cautioned about combined effects with alcohol and other CNS depressants.

### **Drug Interactions**

See WARNINGS and PRECAUTIONS for interaction with CNS drugs and alcohol. Methocarbamol may inhibit the effect of pyridostigmine bromide. Therefore, methocarbamol should be used with caution in patients with myasthenia gravis receiving anticholinesterase agents.

### **Drug/Laboratory Test Interactions**

Methocarbamol may cause a color interference in certain screening tests for 5-hydroxyindoleacetic acid (5-HIAA) using nitrosonaphthol reagent and in screening tests for urinary vanillylmandelic acid (VMA) using the Gitlow method.

### **Carcinogenesis, Mutagenesis, Impairment of Fertility**

Long-term studies to evaluate the carcinogenic potential of methocarbamol have not been performed. No studies have been conducted to assess the effect of methocarbamol on mutagenesis or its potential to impair fertility.

### **Pregnancy**

## **Teratogenic Effects**

### Pregnancy Category C

Animal reproduction studies have not been conducted with methocarbamol. It is also not known whether methocarbamol can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Methocarbamol Tablets USP, 500 mg and 750 mg should be given to a pregnant woman only if clearly needed.

Safe use Methocarbamol Tablets USP, 500 mg and 750 mg has not been established with regard to possible adverse effects upon fetal development. There have been reports of fetal and congenital abnormalities following in utero exposure to methocarbamol. Therefore, Methocarbamol Tablets USP, 500 mg and 750 mg should not be used in women who are or may become pregnant and particularly during early pregnancy unless in the judgment of the physician the potential benefits outweigh the possible hazards (see WARNINGS).

## **Nursing Mothers**

Methocarbamol and/or its metabolites are excreted in the milk of dogs; however, it is not known whether methocarbamol or its metabolites are excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Methocarbamol Tablets USP, 500 mg or 750 mg is administered to a nursing woman.

## **Pediatric Use**

Safety and effectiveness of Methocarbamol Tablets USP, 500 mg and 750 mg in pediatric patients below the age of 16 have not been established.

## **ADVERSE REACTIONS**

Adverse reactions reported coincident with the administration of methocarbamol include:

*Body as a whole:* Anaphylactic reaction, angioneurotic edema, fever, headache

*Cardiovascular system:* Bradycardia, flushing, hypotension, syncope, thrombophlebitis

*Digestive system:* Dyspepsia, jaundice (including cholestatic jaundice), nausea and vomiting  
*Hemic and lymphatic system:* Leukopenia

*Immune system:* Hypersensitivity reactions

*Nervous system:* Amnesia, confusion, diplopia, dizziness or lightheadedness, drowsiness, insomnia, mild muscular incoordination, nystagmus, sedation, seizures (including grand mal), vertigo

*Skin and special senses:* Blurred vision, conjunctivitis, nasal congestion, metallic taste, pruritus, rash, urticaria.

## **OVERDOSAGE**

Limited information is available on the acute toxicity of methocarbamol. Overdose of methocarbamol is frequently in conjunction with alcohol or other CNS depressants and

includes the following symptoms: nausea, drowsiness, blurred vision, hypotension, seizures, and coma.

In post-marketing experience, deaths have been reported with an overdose of methocarbamol alone or in the presence of other CNS depressants, alcohol or psychotropic drugs.

## **Treatment**

Management of overdose includes symptomatic and supportive treatment. Supportive measures include maintenance of an adequate airway, monitoring urinary output and vital signs, and administration of intravenous fluids if necessary. The usefulness of hemodialysis in managing overdose is unknown.

## **DOSAGE AND ADMINISTRATION**

**Methocarbamol Tablets USP, 500 mg** – Adults:

Initial dosage: 3 tablets q.i.d.

Maintenance dosage: 2 tablets q.i.d.

**Methocarbamol Tablets USP, 750 mg** – Adults:

Initial dosage: 2 tablets q.i.d.

Maintenance dosage: 1 tablet q.4h. or 2 tablets t.i.d.

Six grams a day are recommended for the first 48 to 72 hours of treatment. (For severe conditions 8 grams a day may be administered). Thereafter, the dosage can usually be reduced to approximately 4 grams a day.

## **HOW SUPPLIED**

Product: 53002-3041

NDC: 53002-3041-1 10 TABLET, FILM COATED in a BOTTLE

NDC: 53002-3041-2 20 TABLET, FILM COATED in a BOTTLE

NDC: 53002-3041-3 30 TABLET, FILM COATED in a BOTTLE

NDC: 53002-3041-6 60 TABLET, FILM COATED in a BOTTLE

## **Methocarbamol 500mg Tablets, USP**

NDC 53002-3041-3 30 TABLETS 30 TABLETS  
 METHOCARBAMOL 500MG TABLETS, USP  
 LIST# 76385-123-01  
 LOT# 21348-009  
 EXP: 04-30-2023  
 ORDER# 314-30  
**Rx only**  
 LIGHT ORANGE ROUND TABLET B104 SCORED  
 EACH TABLET CONTAINS: METHOCARBAMOL, USP 500MG  
 THIS IS A MUSCLE RELAXANT. MAY CAUSE DROWSINESS, ALCOHOL, CNS DEPRESSANTS, OTHER DRUGS, BLOOD ALCOHOL/URIC ACID. CAUTION WHEN OPERATING A CAR OR HEAVY MACHINERY.  
 CLINIC NAME GOES HERE  
 Date Dispensed: \_\_\_\_\_  
 Patient Name: \_\_\_\_\_  
 Prescriber Name: \_\_\_\_\_  
 Refill: 213580061000 ORDER# 314-30  
 BAYSHORE PHARM-Generics for ROBIAXON 500MG  
**3 TABLETS 4 TIMES A DAY FOR 48-72 HOURS; THEN 2 TABLETS 4 TIMES A DAY.**  
 30413  
 03002  
 METHOCARBAMOL 500MG TABLETS  
 PATIENT NAME  
 PRESCRIBER'S NAME  
 LOT# 21348-009 EXP 04-30-2023  
 Refill: 213580061000 FDA-3041  
 30 ea METHOCARBAMOL 500MG TABLETS  
 BILLING NDC# 76385-0123-01  
 Refill: 213580061000  
 30 ea METHOCARBAMOL 500MG TABLETS  
 BILLING NDC# 76385-0123-01  
 Refill: 213580061000  
 30 ea METHOCARBAMOL 500MG TABLETS  
 BILLING NDC# 76385-0123-01  
 Refill: 213580061000  
 30 ea METHOCARBAMOL 500MG TABLETS  
 DISCARD BY 04-30-2023  
 NDC# 53002-3041-3 Refill: 213580061000  
 FOR FULL LABORATORY REPORT OF THIS INDICATION  
 ANY PRESCRIPTION THAT THE PRESCRIBER PRESENTS  
 PRESCRIBER: KEEP THIS ALL MEDICAL RECORDS OF THE  
 REACH OF CHILDREN. CALL YOUR DOCTOR FOR MEDICAL  
 ADVISE ABOUT SIDE EFFECTS. YOU MAY REPORT SIDE  
 EFFECTS TO FDA AT 1-800-FDA-1088  
 Clinic Name Here  
 PRESCRIBER NAME DATE  
 PATIENT NAME

# METHOCARBAMOL

methocarbamol tablet, film coated

## Product Information

<b>Product Type</b>	HUMAN PRESCRIPTION DRUG	<b>Item Code (Source)</b>	NDC:53002-3041(NDC:76385-123)
<b>Route of Administration</b>	ORAL		

## Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
<b>METHOCARBAMOL</b> (UNII: 125OD7737X) (METHOCARBAMOL - UNII:125OD7737X)	METHOCARBAMOL	500 mg

## Inactive Ingredients

Ingredient Name	Strength
<b>STARCH, CORN</b> (UNII: O8232NY3SJ)	
<b>LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE, UNSPECIFIED</b> (UNII: 2165RE0K14)	
<b>SODIUM STARCH GLYCOLATE TYPE A POTATO</b> (UNII: 5856J3G2A2)	
<b>POVIDONE, UNSPECIFIED</b> (UNII: FZ989GH94E)	
<b>SODIUM LAURYL SULFATE</b> (UNII: 368GB5141J)	
<b>SILICON DIOXIDE</b> (UNII: ETJ7Z6XBU4)	
<b>STEARIC ACID</b> (UNII: 4ELV7Z65AP)	
<b>MAGNESIUM STEARATE</b> (UNII: 70097M6130)	
<b>WATER</b> (UNII: 059QF0KO0R)	
<b>HYPROMELLOSE, UNSPECIFIED</b> (UNII: 3NXW29V3WO)	
<b>TITANIUM DIOXIDE</b> (UNII: 15FIX9V2JP)	
<b>PROPYLENE GLYCOL</b> (UNII: 6DC9Q167V3)	
<b>FD&amp;C YELLOW NO. 6</b> (UNII: H77VEI93A8)	
<b>POLYSORBATE 20</b> (UNII: 7T1F30V5YH)	

## Product Characteristics

<b>Color</b>	orange (light orange)	<b>Score</b>	2 pieces
<b>Shape</b>	ROUND	<b>Size</b>	13mm

<b>Flavor</b>		<b>Imprint Code</b>	B134	
<b>Contains</b>				
<b>Packaging</b>				
#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:53002-3041-1	10 in 1 BOTTLE; Type 0: Not a Combination Product	07/01/2022	
2	NDC:53002-3041-6	60 in 1 BOTTLE; Type 0: Not a Combination Product	07/01/2022	
3	NDC:53002-3041-2	20 in 1 BOTTLE; Type 0: Not a Combination Product	07/01/2022	
4	NDC:53002-3041-3	30 in 1 BOTTLE; Type 0: Not a Combination Product	07/01/2022	
<b>Marketing Information</b>				
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date	
ANDA	ANDA208507	01/15/2018		

**Labeler** - RPK Pharmaceuticals, Inc. (147096275)

### Establishment

Name	Address	ID/FEI	Business Operations
RPK Pharmaceuticals, Inc.		147096275	RELABEL(53002-3041) , REPACK(53002-3041)

Revised: 3/2022

RPK Pharmaceuticals, Inc.